Cambridge Biotechnology proves worth with
News | 18 June 2012
A 93-year old US pharmaceutical, is to spend up to
Click on the link to read the full article at Cabume - Cambridge technology news
(This link will open in a new window)
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
